Biopharma companies are increasingly adopting RWE to drive efficiencies in drug research and development. From informing early stage planning to supporting label expansions, RWE research methods are enabling R&D teams to make more informed decisions, faster.
In this webinar, hear from global biopharma leaders and Aetion about how and where RWE can enable more agile research approaches to accelerate drug development.
You will also hear about:
- Updates on the state of RWE in 2021, including trends in regulatory approvals and anticipated guidances this year
- Examples of how biopharma can use RWE to inform trial feasibility and design, to test lab-developed hypotheses, and to support label expansion
- How global biopharma companies are integrating RWE across their R&D teams, with insight into trends and best practices for operationalizing adoption
Click here for additional information and registration details.
Related Content
Evidence Matters 2022
Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.
Achieving Consensus When Everyone is an Expert, but No One Agrees
Join experts from PHAR, Novartis, and Bausch Health for a discussion around the Delphi panels and how the results are used.
Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to Achieve Optimal Access
Experts will present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.